Table 3.

Nuclear translocation of NFAT-2 in human keratocytes

Treatment	NFAT-2
	% cells showing nuclear positivity	Number of cells counted
Medium control*	6.7	150
DMSO control†	6.7	150
Ionomycin 2h‡	14.7§§	150
Ionomycin 4h‡	56.0§§§	150
Ionomycin 18 h‡	75.3§§§	150
CsA 2h¶	6.7	150
CsA 4 h¶	8.7	150
CsA 18 h¶	8.0	150
Tacrolimus 2 h∥	6.0	150
Tacrolimus 4 h∥	6.7	150
Tacrolimus 18 h∥	6.0	150
Retinoic acid 2 h**	7.3	150
Retinoic acid 4 h**	7.3	150
Retinoic acid 18 h**	12.7	150
TGF-β 2 h§	7.3	150
TGF-β 4 h§	8.0	150
TGF-β 18 h§	8.7	150
1,25(OH)2D3 2 h#	7.3	150
1,25(OH)2D3 4 h#	47.3##	150
1,25(OH)2D3 18 h#	52.0##	150

^*Low calcium (70 μM) medium,

^†Vehicle control,

^‡Ionomycin (1 μM),

^¶CsA (1 μM),

^∥Tacrolimus (1 μM),

^**Retinoic acid (100 nM),

^§TGF-β (1ng/ml),

^#1, 25 (OH)₂D₃ (100nM),

^§§P=0.04 compared to DMSO control,

^§§§P<0.0001 compared to DMSO control,

^##P<0.0001 compared to DMSO control.